| Literature DB >> 33790869 |
Ying Guo1, Lili You1, Huijun Hu2, Anli Tong3, Xiaoyun Zhang1, Li Yan1, Shaoling Zhang1.
Abstract
Purpose: Surgery is the major treatment option for pheochromocytoma but carries potential risks, including hemorrhage and hemodynamic instability. Even with laparoscopic adrenalectomy, intraoperative blood transfusion happens from time to time, but few studies have investigated risk factors. For the first time we develop and validate a nomogram for prediction of red blood cell transfusion in pheochromocytoma surgery.Entities:
Keywords: blood transfusion; nomogram; pheochromocytoma; prediction model; surgery
Mesh:
Substances:
Year: 2021 PMID: 33790869 PMCID: PMC8006300 DOI: 10.3389/fendo.2021.647610
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Comparison between RBC transfusion and non-RBC transfusion groups.
| Variables | Training data set (n = 189) | Validation data set (n = 57) | ||||
|---|---|---|---|---|---|---|
| Transfusion (n = 61) | Non-transfusion (n = 128) | P-value | Transfusion (n = 12) | Non-transfusion (n = 45) | P-value | |
| Male | 27 (44.26%) | 59 (46.09%) | 0.936 | 8 (66.67%) | 19 (42.22%) | 0.237 |
| Age, years | 43.0 (33.0,52.0) | 49.0 (33.0, 57.5) | 0.131 | 44.0 (39.0, 57.5) | 50.0 (37.0, 56.0) | 0.652 |
| Family history | 3 (4.92%) | 3 (2.34%) | 0.345 | 1 (8.33%) | 2 (4.44%) | 0.529 |
| Hypertension | 51 (83.61%) | 103 (80.47%) | 0.604 | 11 (91.67%) | 36 (80.00%) | 0.345 |
| Elevated catecholamines | 53 (86.89%) | 107 (83.59%) | 0.821 | 11 (91.67%) | 34 (75.56%) | 0.224 |
| Tumor diameter, mm | 67.53 ± 32.39 | 44.60 ± 18.00 | <0.001 | 69.67 ± 38.89 | 47.57 ± 22.63 | 0.082 |
| PBZ use | 59 (96.72%) | 119 (92.97%) | 0.303 | 12 (100%) | 41 (91.11%) | 0.284 |
| PBZ duration, day | 20.36 ± 8.64 | 17.09 ± 10.33 | 0.024 | 16.00 ± 3.52 | 20.44 ± 18.58 | 0.138 |
| Preoperative SBP fluctuation, mm Hg | 35.93 ± 16.72 | 30.96 ± 13.26 | 0.044 | 33.83 ± 19.31 | 29.04 ± 12.65 | 0.43 |
| Preoperative DBP fluctuation, mm Hg | 22.03 ± 10.10 | 20.87 ± 8.41 | 0.436 | 21.75 ± 11.41 | 21.07 ± 10.19 | 0.853 |
| Preinduction SBP, mm Hg | 130.00 (118.00, 142.00) | 132.00 (115.00, 141.00) | 0.786 | 126.00 (118.00, 146.25) | 127.00 (115.00, 141.00) | 0.695 |
| Preinduction DBP, mm Hg | 80.00 (72.00, 92.00) | 77.50 (70.00, 87.00) | 0.190 | 80.00 (76.00, 87.75) | 79.00 (72.00, 87.00) | 0.557 |
| Preinduction HR, bpm | 88.00 (80.00, 93.00) | 80.00 (73.00, 88.00) | <0.001 | 90.50 (81.50, 96.00) | 80.00 (74.00, 84.00) | 0.011 |
| Laparoscope adrenalectomy | 35 (57.38%) | 120 (93.75%) | <0.001 | 6 (50%) | 40 (88.89%) | 0.002 |
| Open Surgery | 26 (42.62%) | 8 (6.25%) | 6 (50%) | 5 (11.11%) | ||
RBC, red blood cell; PBZ, phenoxybenzamine; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.
Figure 1Texture feature selection using the least absolute shrinkage and selection operator (LASSO) logistic regression model. (A) LASSO coefficient profiles of the 32 texture features. (B) Tuning parameter (lambda) selection in the LASSO model used 10-fold cross-validation via minimum criteria for risk of intraoperative RBC transfusion.
Risk factor analysis of intraoperative RBC transfusion.
| Intercept and variable | Model in training dataset | ||
|---|---|---|---|
| β | OR(95%CI) | P-value | |
| Intercept | −9.918 | <0.001 | |
| PBZ Use | 2.590 | 13.32 (1.48–197.38) | 0.034 |
| PBZ Treatment Duration | 0.035 | 1.04 (0.99–1.08) | 0.092 |
| Preinduction HR | 0.044 | 1.04 (1.01–1.08) | 0.006 |
| Tumor Diameter | 0.034 | 1.03 (1.02–1.06) | <0.001 |
| Surgical Procedure | 2.841 | 17.13 (5.18–78.79) | <0.001 |
β is the regression coefficient.
RBC, red blood cell; OR, odd ratio; PBZ, phenoxybenzamine; HR, heart rate.
Figure 2Nomogram for predicting intraoperative RBC transfusion. The nomogram was developed in the training set, with the phenoxybenzamine use, phenoxybenzamine treatment duration, preinduction heart rate, tumor diameter and surgical procedure incorporated.
Figure 3Receiver operating characteristic (ROC) curves for evaluating the nomogram model’s discrimination performance in both training and validation sets. (A) ROC curve of the nomogram in the training set. (B) ROC curve of the nomogram in the internal validation set. (C) ROC curve of the nomogram in the external validation set. The AUC of ROC curves plot sensitivity against 1-specificity of the nomogram.
Figure 4Decision curve analysis for the nomogram model of intraoperative RBC transfusion in training set, internal validation set and external validation set. The y-axis measures the net benefit. The x-axis indicates the threshold probability of the risk of intraoperative RBC transfusion. The green line represents the nomogram in training set, while the red one represents the nomogram in internal validation set and the blue one represents that in external validation set. The grey line represents the assumption that all patients have intraoperative RBC transfusion. Thin black line represents the assumption that no patient has intraoperative RBC transfusion.